The approval marks a significant shift for stage IV pancreatic cancer management. Daraxonrasib, marketed as Rasonque by Revolution Medicines, Inc., is specifically indicated for patients who have exhausted at least one prior systemic therapy or are unable to tolerate multiagent chemotherapy. According to Dr. Najeeb Al Hallak, who led the trial at Karmanos, the drug functions by targeting active forms of the RAS protein family, the primary drivers of tumor growth in most pancreatic adenocarcinomas.
Karmanos Introduces FDA-Approved Daraxonrasib for Metastatic Pancreatic Cancer
Patients battling metastatic pancreatic adenocarcinoma now have a new oral treatment option following the FDA’s August 26, 2026, approval of daraxonrasib. The Barbara Ann Karmanos Cancer Institute in Detroit, which helped spearhead the pivotal RASolute 302 clinical trial, has officially begun offering the therapy to eligible adults.
Data from the randomized RASolute 302 study of 500 participants demonstrated a clear survival benefit. Patients receiving daraxonrasib achieved a median overall survival of 13.2 months, nearly doubling the 6.7-month outcome observed in those treated with standard chemotherapy. While 61.8% of patients on the new therapy experienced severe side effects, the rate of treatment discontinuation was notably low at 1.2%, compared to 11.2% in the chemotherapy control group. With the National Cancer Institute projecting over 67,000 new pancreatic cancer diagnoses in 2026, the availability of this once-daily oral tablet provides a critical alternative for a demographic with historically limited options.
Comments (0)
No comments yet. Be the first!